Studies validated a new test can predict risk of breast cancer recurrence in a sizable group of patients
On Dec. 7, 2005, results from several studies presented at the San Antonio Breast Cancer Symposium validated that…
Biotechnology | Diagnostics | NIH | Non-Profit Research | Oncology | Therapeutics | U.S. Congress | Women's Health
The 2-Year Extension of Postage Stamp for Breast Cancer Research (PL 109-100) was extended
On Nov. 11, 2005, the U.S. Congress authorized the 2-year extension of Postage Stamp for Breast Cancer Research…
Preliminary results from clinical trial of digital vs. film mammography showed no difference in breast cancer detection
On Sept. 16, 2005, preliminary results from a large, clinical trial of digital vs. film mammography showed no…
NCI-sponsored clinical trials showed patients with early-stage, HER2-positive, invasive breast cancer experienced decrease in risk of cancer recurrence
On Apr. 27, 2005, results from two large National Cancer Institute sponsored randomized clinical trials showed that patients…
NCI trial reported targeted agent trastuzumab and standard chemo cut risk of HER-2-positive breast cancer
On Apr. 25, 2005, the combination of the targeted agent trastuzumab (Herceptin) and standard chemotherapy cuts the risk…
Biotechnology | Diagnostics | Disease | FDA | Nanotechnology | Oncology | Therapeutics
FDA approved albumin-stabilized nanoparticle formulation of paclitaxel for treatment of breast cancer
In Jan. 2005, the U.S. Food and Drug Administration (FDA) approved an albumin-stabilized nanoparticle formulation of paclitaxel (Abraxane)…
The National Cancer Institute study determined that a new molecular test can predict the risk of breast cancer recurrence
On Dec. 10, 2004, a National Cancer Institute (NCI) supported study determined that a new molecular test done…
Biotechnology | Disease | FDA | Oncology | Therapeutics | Women's Health
Letrozole was approved by the FDA for the adjuvant treatment of early-stage breast cancer after five years of tamoxifen therapy
On Oct. 29, 2004, the U.S. Food and Drug Administration (FDA) approved Letrozole for the extended adjuvant treatment…
Women’s Health Initiative data showed women who take estrogen with hormone progestin have greater risk of developing breast cancer
In 2004, data from the Women’s Health Initiative (WHI) study show that women who take estrogen in combination…
World’s first use of low-dose radioactive palladium ‘seeds’ was used to treat breast cancer patients at the Women’s Research Institute in Toronto.
In 2004, the world’s first use of low-dose radioactive palladium ‘seeds’ as used to treat breast cancer patients…
A novel approach to treatment of solid cancers involved therapeutic agents that inhibit the generation of new blood vessels in growing tumors
On Nov. 19, 2003, a novel approach to treatment of solid cancers involved therapeutic agents that inhibit the…
A clinical trial found post-menopausal survivors of early-stage breast cancer who took letrozole reduced risk of cancer recurrence
On Oct. 9, 2003, a Canadian-led international clinical trial found that post-menopausal survivors of early-stage breast cancer who…
Death rates from the lung, breast, prostate, and colorectal cancers continued to decline in the late 1990s
On Sept. 3, 2003, the death rates from the four most common cancers, – lung, breast, prostate, and…
Biotechnology | Diagnostics | Disease | NIH | Oncology | Radiology | Therapeutics
NCI clinical trial showed reduced intervals between chemotherapy improved survival in women whose breast cancer had spread to lymph nodes
On Dec. 12, 2002, the National Cancer Institute (NCI) announced that a clinical trial had shown that reducing…
Los Angeles Cancer Center Received $15 Million for Woman’s Health Center
On Mar. 26, 2005, The University of Southern California/Norris Comprehensive Cancer Center in Los Angeles announced a $15…
National Cancer Institute and ACRIN launched first multicenter study to compare digital mammography
On Sept. 4. 2001, the National Cancer Institute (NCI) and the American College of Radiology Imaging Network launched…
OMRF researchers found that BRCA1 and BRCA2 genes may predict breast cancer risk in women
On May 24, 2001, Dr. Eldon Jupe and a team of Oklahoma Medical Research Foundation (OMRF) researchers found…
Biotechnology | Diagnostics | NIH | Non-Profit Research | Oncology | Therapeutics | U.S. Congress | Women's Health
President Bill Clinton signed into law the Semipostal Authorization Act
On Jul. 28, 2000, President Bill Clinton signed into law the Semipostal Authorization Act (P.L. 106-253), which gave…
The Study of Tamoxifen and Raloxifene began recruiting volunteers
On May 25, 1999. the Study of Tamoxifen and Raloxifene, or STAR, one of the largest breast cancer…
Siteman Cancer Center investigators joined the STAR (Study of Tamoxifen and Raloxifene) trial for breast cancer prevention
In 1999, Siteman Cancer Center investigators joined the STAR (Study of Tamoxifen and Raloxifene) trial for breast cancer…
Biotechnology | Diagnostics | Disease | FDA | Oncology | Therapeutics | Women's Health
The FDA approved the monoclonal antibody Herceptin (Trastuzumab) for treatment of metastatic breast cancer
On Sept. 25, 1998, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody Herceptin (Trastuzumab) for…
Breast Cancer Prevention Trial Results published
On Sept. 14, 1998, researchers from the Breast Cancer Prevention Trial (BCPT) published a full report and update…
Biotechnology | Diagnostics | NIH | Non-Profit Research | Oncology | Therapeutics | U.S. Congress | Women's Health
The Stamp Out Breast Cancer stamp was first issued
On Jul. 29, 1998, the Stamp Out Breast Cancer stamp was first issued. The driving force behind the…
Biotechnology | Diagnostics | Disease | Medical Device | Oncology | Radiology | U.S. Congress | Women's Health
Mammography Quality Standards Reauthorization Act continued 1992 Act until 2002
In 1998, the Mammography Quality Standards Reauthorization Act (MQSA) was passed by the U.S. Congress and continued the…
Tamoxifen, created with the MCF-7 breast cancer cell line established by Karmanos, reduced the incidence of some breast cancer outcomes
In 1998, Tamoxifen, created with the MCF-7 breast cancer cell line established by Karmanos, was revealed to reduce…
Biotechnology | Diagnostics | NIH | Non-Profit Research | Oncology | Therapeutics | U.S. Congress | Women's Health
The Stamp Out Breast Cancer Act (PL 105-41) was signed into law
On Aug. 13, 1997, the Stamp Out Breast Cancer Act (PL 105-41) was signed into law by President…
the Art behind the Breast Cancer Research Postage Stamp
In August 1997, the U.S. Congress passed legislation that directed the U.S. Postal Service to issue its first…
Biotechnology | Diagnostics | Disease | FDA | Therapeutics | Women's Health
The FDA approved anastrozole (Arimidex) as a treatment for breast cancer
In January 1996, the U.S. Food and Drug Administration (FDA) approved anastrozole (Arimidex) as a treatment for breast…
BRCA2 gene mapped to chromosome 13q12-13
In 1995, The BRCA2 gene was mapped to chromosomal 13q. Just fifteen months later, Wooster et al. reported…
Scientists cloned the tumor suppressor genes BRCA1 and BRCA2
In 1995, scientists cloned the tumor suppressor genes BRCA1 and BRCA2, inherited genetic mutations that can predict an…